Skip to Main Content

News Center

Generic Drugs

UMB Conducts First-of-a-Kind Study on Bioequivalency of Anti-Epileptic Drug

August 14, 2015

Collaborative study helps validate effectiveness of FDA’s bioequivalence standard, showing no significant differences between major brand name and generic medication used to treat patients with epilepsy.

SOP’s Polli Testifies for GDUFA Renewal at National Public Meeting

August 6, 2015

Testimony examined the impact of FDA-supported research in generic drugs and advocated for continued funding through renewal of the Generic Drug User Fee Amendments of 2012 (GDUFA).

SOP Faculty Receive $1.5 Million from the FDA to Study Iron Medications

February 24, 2015

Interdisciplinary group will research the effectiveness of brand versus generic iron medications used to treat anemia in kidney disease patients

FDA Awards Two Grants, $1.2 Million to Center for Translational Medicine

January 12, 2015

Grants will support the development of quantitative pharmacometric models to advance the evaluation of generic drugs.

SOP Faculty Testify During FDA Generic Drug Regulation Public Meeting

July 3, 2013

Drs. Hoag and Polli examine current regulatory science initiatives aimed at generic drugs and discuss ways in which existing initiatives can be improved.

SOP Hosts World-Renowned Researchers During CERSI-Sponsored Conferences

June 4, 2013

New developments in pharmaceutical manufacturing and topical drug bioequivalence and bioavailability addressed in two day-long workshops.

Ellis S. Grollman Lecture Brings Leaders in Pharmaceutical Sciences to SOP

November 15, 2012

Leslie Benet, PhD, professor and former chair of the Department of Bioengineering and Therapeutic Sciences at the University of California, San Francisco (UCSF), delivers keynote address.